Refractory Malignant Solid Neoplasm Recruiting Phase 1 Trials for Aflibercept (DB08885)

IndicationStatusPhase
DBCOND0088735 (Refractory Malignant Solid Neoplasm)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02159989Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTreatment